Navigation Links
Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
Date:11/2/2007

More About the REPEAT Study

Enrolling 950 patients from Europe, North America and Latin America, REPEAT (REtreatment with PEgasys in pATients Not Responding to Peg-Intron Therapy) was designed to explore whether intensified treatment with a higher fixed-dose induction of PEGASYS in combination with COPEGUS and/or longer treatment duration may increase treatment success rates in patients who didn't respond to at least twelve weeks of Peg-Intron/ribavirin combination therapy. Patients were randomized 2:1:1:2 to one of four regimens:

-- Patients in arms A (n=318) and B (n=158) received PEGASYS 360 mcg/week

for 12 weeks, followed by 180 mcg/week for a further 60 or 36 weeks,

respectively

-- Patients in arms C (n=158) and D (n=316) received PEGASYS 180 mcg/week

for 72 or 48 weeks, respectively

-- All patients received COPEGUS (1,000/1,200 mg/day) in combination with

PEGASYS

Results showed:

-- The primary endpoint was met: SVR, defined by undetectable hepatitis C

virus RNA in the blood six months after the end of treatment, was

significantly higher for arm A (16 percent) compared to arm D (nine

percent)

-- A pooled analysis of the 72-week arms vs. the 48-week arms showed that

72 weeks of treatment had the biggest impact on success of treatment,

with a doubling of SVR rate compared to 48 weeks (16 percent vs. eight

percent). A pooled analysis of the induction dose arms vs. standard

dose arms showed that treatment with higher fixed-dose induction for

this difficult-to-treat patient population did not provide significant

additional benefit

-- Response at 12 weeks was a strong predictor of successful treatment

-- Of patients whose virus was undetectable after 12 weeks of therapy,

57 percent in the 72-week arms went on to achieve treatment success

(by comparison, among patient
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Rapid HIV Testing Increases Possibility of Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MOUNTAIN VIEW, Calif., July 31, 2014 IRIDEX Corporation ... the second quarter and six months ended June 28, 2014.  ... quarter of 2014, up 15% from $9.2 million in the ... the first quarter of 2014. Revenues for the first six ... million in the first six months of last year. ...
(Date:7/31/2014)... 31, 2014  Cepheid (NASDAQ: CPHD ) today ... conferences, and invited investors to participate via webcast. ... New York, NY Wednesday, August 13, 2014 at ... Conference, New York, NY Thursday, September ... Accessing Live Webcasts To access the live webcasts for these ...
(Date:7/31/2014)... 2014 Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... the development of its lead molecule, Anatabine Citrate, in ... selected Quotient Clinical, The Translational Pharmaceutics Company, based in ... run its early development programs. The Company ... the end of the third quarter with the Medicines ...
Breaking Medicine Technology:IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Cepheid to Webcast Upcoming Financial Presentations 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4
(Date:8/2/2014)... When the Black Hat conventioneers descend on Las Vegas ... can be always counted on, plenty of FUD will be ... doubt. The run-up has already made its share of ... on July 31st about how hackers could use a ... infect a system with malware, completely undetected, by leveraging the ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Cannabis use among ... teens aged 14 to 17 having used marijuana at least ... With their slogan “Say ‘No’ to Drugs, Say ‘Yes to ... reaching out to youth this summer with factual information about ... past six months, Hamburg “Say ‘No’ to Drugs, Say ‘Yes’ ...
(Date:8/1/2014)... a central role in regulating appetite and whole-body metabolism. ... brain,s control of food intake and body weight, but ... been unclear. A new study in the ... activity in a type of neuron known as pro-opiomelanocortin ... high-fat diet. Sabrina Diano and colleagues at Yale ...
(Date:8/1/2014)... Aug. 1, 2014 (HealthDay News) -- The U.S. Food ... a new drug, Jardiance, to help fight type 2 ... or added to existing treatment regimens to control blood ... Curtis Rosebraugh, director of the Office of Drug Evaluation ... Research, said in an agency statement. The FDA ...
(Date:8/1/2014)... Summer is here, and with it comes ... summer, and they can be a pain for dogs. Animal ... all their customers get rid of ticks and prevent them ... in the summer, which is why they are so active ... and woodland areas and carry a number of diseases, including ...
Breaking Medicine News(10 mins):Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 2Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 3Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 4Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 5Health News:Addressing a Serious Issue Affecting German Teens 2Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:Tis the Season for Tick Prevention 2
... University of New Hampshire finds that U.S. children are routinely ... previously recognized, with nearly half experiencing a physical assault in ... abuse and crime than do adults," said David Finkelhor, director ... study director. "If life were this dangerous for ordinary grown-ups, ...
... BANGKOK, Oct. 6 As thousands of experts around ... health and nutrition at the International Congress of Nutrition ... and Mars, Incorporated are acknowledging the important impact of ... Science - Flavanols and Sustainability," scientists will present evidence ...
... Los Angeles back surgeon, Dr. Rezaian of the California Orthopedic ... Spinal Stenosis . Open back surgery used to be ... pinching nerves, however, recent medical advances have given patients requiring ... of hope. Doctors have pioneered a new laser Spinal Stenosis ...
... ANGELES, Oct. 6 The Renaissance Laser and Vein Institute offers ... stretch marks and sagging skin like never before. Thanks to recent ... skin care lasers in the dermatological and cosmetic skin care world. ... is the Titan Procedure . The Titan laser ...
... Pelosi and the Democratic Women,s Working Group joined leaders from women,s ... discuss how women stand to gain the most ... face discrimination in both coverage and cost if health reform fails. ... , On Why Health Insurance Reform is Essential for ...
... D.D.S., who practices general dentistry in Flint, Mich., was inducted ... during a meeting of the ADA House of Delegates in ... presidency in October 2010 and will lead the more than ... Gist will be the ADA,s first African-American president. , Dr. ...
Cached Medicine News:Health News:New study finds high rates of childhood exposure to violence and abuse in US 2Health News:Cocoa Research Finds a Place in the Global Health Dialogue 2Health News:Cocoa Research Finds a Place in the Global Health Dialogue 3Health News:Cocoa Research Finds a Place in the Global Health Dialogue 4Health News:Cocoa Research Finds a Place in the Global Health Dialogue 5Health News:California Surgeon (laserbacksurgery.com) Pioneers Exciting Alternative to Traditional Spinal Stenosis Treatment 2Health News:Southern California Renaissance Laser and Vein Institute (laserandveinclinic.com) Offers Cutting Edge New Titan Procedure 2Health News:Pelosi: Health Insurance Reform Essential for Women 2Health News:Pelosi: Health Insurance Reform Essential for Women 3Health News:Pelosi: Health Insurance Reform Essential for Women 4Health News:Pelosi: Health Insurance Reform Essential for Women 5Health News:Michigan Dentist Chosen President-Elect of the American Dental Association 2
... Injection is supplied in an isotonic solution ... intravenous administration. Each milliliter contains 37 megabecquerels ... calibration time, made isotonic with 9 milligrams ... benzyl alcohol. The pH is adjusted to ...
... single-detector system offers general purpose ... for gurneys and wheelchairs. This ... versatile open gantry, caudal/cephalic detector ... for SPECT and whole body ...
Stainless steel lancet blade in stainless steel....
Sharp diamond shaped double blade in stainless steel....
Medicine Products: